Qualigen Therapeutics Inc (QLGN) Actualités

Form 8-K - Current report

Form EFFECT - Notice of Effectiveness

Form S-1 - General form for registration of securities under the Securities Act of 1933

Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement

Carlsbad, CA, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics (NASDAQ: QLGN) (the “Company” or...

Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC...

Form D - Notice of Exempt Offering of Securities

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares

Carlsbad, CA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the...

Form 3 - Initial statement of beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024

CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the...